Back to Newsroom

Cempra’s Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity

Cempra, Inc. to Present Late-Breaker on Solithromycin’s Anti-NASH Effects in an Animal Model at DDW 2014

CHAPEL HILL, N.C., April 3, 2014 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP) today announced the presentation of a late-breaking abstract entitled “Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model,” at 9:15 a.m. EDT, May 6, at Digestive Disease Week (DDW®) 2014 in Room S105A at McCormick Place in Chicago. The presentation will be included in the session entitled “Basic Late Breaking Abstract Session.”

Additional information on the conference can be found on the DDW 2014 website: